BioNTech SE (BNTX) saw its stock price surge by 6.22% during the trading session, driven by positive news regarding its lung cancer drug, Gotistobart.
The company, in collaboration with Oncoc4, announced clinically meaningful overall survival benefits for Gotistobart in patients with previously treated squamous non-small cell lung cancer. The drug demonstrated a reduction in the risk of death by more than half compared to standard chemotherapy and has been granted Fast Track designation by the U.S. FDA. This development has significantly boosted investor confidence in BioNTech's pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments